Phase I/II Trial of Labetuzumab Govitecan (Anti-CEACAM5/SN-38 Antibody-Drug Conjugate) in Patients With Refractory or Relapsing Metastatic Colorectal Cancer

The objectives were to evaluate dosing schedules of labetuzumab govitecan, an antibody-drug conjugate targeting carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) for tumor delivery of 7-ethyl-10-hydroxycamptothecin (SN-38), in an expanded phase II trial of patients with relapsed or...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Clin Oncol
Päätekijät: Dotan, Efrat, Cohen, Steven J., Starodub, Alexander N., Lieu, Christopher H., Messersmith, Wells A., Simpson, Pamela S., Guarino, Michael J., Marshall, John L., Goldberg, Richard M., Hecht, J. Randolph, Wegener, William A., Sharkey, Robert M., Govindan, Serengulam V., Goldenberg, David M., Berlin, Jordan D.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Clinical Oncology 2017
Aiheet:
ORIGINAL REPORTS
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8259133/
https://ncbi.nlm.nih.gov/pubmed/28817371
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2017.73.9011
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia